Ligase Targeting Drug Development Summit - May 2021 - Digital Event

Memo

As the therapeutic value of manipulating previously hard-to-drug ubiquitin ligases becomes more and more evident in addressing numerous diseases with unmet clinical needs, the inaugural Ligase Targeting Drug Development Summit arrives as the dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to seize the day. Built with large pharma and biotech insight, the Ligase Targeting Drug Development Summit is fully dedicated to enabling novel ligase discovery and characterization, achieving cell and tissue specificity and expanding chemical biology tools to therapeutically leverage ubiquitin ligases for effective protein modulation or degradation strategies. As leading pharma companies join forces to bridge the gap between the functional knowledge and true translational value of ubiquitin ligases and their associated ligands, join us to advance your understanding, differentiate your pipelines and tap into the uncapped therapeutic potentials of this emerging field. Take advantage of our group discounts, academic rates and earlybird savings - don't miss out register now for the best rate! URLs:Tickets: https://go.evvnt.com/717315-2?pid=5569Brochure: https://go.evvnt.com/717315-3?pid=5569 Prices:Conference Only: USD 1999.0,Conference + 1 Workshop: USD 2348.0,Conference + 2 Workshops: USD 2697.0 Speakers: Chris De Savi Vice President Head of Drug Discovery Kymera, Miklos Bekes Senior Research Investigator and Group Leader in Platform Biology Arvinas, Daniel Nomura Professor of Chemistry, University of California Berkeley, Alex Bullock Associate Professor, University of Oxford Centre for Medicines Discovery, Benedict Cross Chief Technology Officer PhoreMost Ltd, Claudio Thomas Senior Principal Scientist Novartis Institutes for Biomed Research, Inc, Ingo Hartung Director Medicinal Chemistry Merck, Joe Patel Senior Director C4 Therapeutics, Nicholas Brown Assistant Professor University of North Carolina, Rick Davies Associate Director AstraZeneca Pharmaceuticals, Ryan Potts Executive Director and Head of IPP Amgen, Kumar Suresh Senior Director R and D Progenra Inc, Roman Erdmann Senior Scientist Merck, Yue Xiong CSO Cullgen Inc, Nicolas Thomä Senior Group Leader Friedrich Miescher Institute for Biomedical Research in Basel, Radosław Nowak Scientist, Cancer Biology Dana-Farber Cancer Institute, Danny Huang Senior Group Leader and Professor of Cancer Structural Biology University of Glasgow, Matthew Calabrese Senior Director and Head of Structural and Molecular Sciences Pfizer, Feng Wang Lab Head of Protein Homeostasis and Principal Scientist Pfizer, Pengyu Yang Associate Director Plexium, Markus Queisser Scientific Leader GlaxoSmithKline, Nico Zinn Group Leader Mass Spectrometry Cellzome, Jeff McKenna Associate Director, Global Discovery Chemistry Novartis Institutes for BioMedical Research Date and Time: On Tuesday May 25, 2021 at 8:30 am (ends Thursday May 27, 2021 at 5:00 pm)